key: cord-0703050-uqp6maxn
authors: Noy-Porat, Tal; Mechaly, Adva; Levy, Yinon; Makdasi, Efi; Alcalay, Ron; Gur, David; Aftalion, Moshe; Falach, Reut; Ben-Arye, Shani Leviatan; Lazar, Shirley; Zauberman, Ayelet; Epstein, Eyal; Chitlaru, Theodor; Weiss, Shay; Achdout, Hagit; Edgeworth, Jonathan D.; Kikkeri, Raghavendra; Yu, Hai; Chen, Xi; Yitzhaki, Shmuel; Shapira, Shmuel C.; Padler-Karavani, Vered; Mazor, Ohad; Rosenfeld, Ronit
title: Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
date: 2021-04-26
journal: iScience
DOI: 10.1016/j.isci.2021.102479
sha: 9473b7c0cc175c8fb6f3ffd9966d950abc0a5cb4
doc_id: 703050
cord_uid: uqp6maxn

Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion that antibody treatments need to rely on highly neutralizing monoclonal antibodies (mAbs), targeting several distinct epitopes for circumventing therapy escape-mutants. Previously, we reported efficient human therapeutic mAbs recognizing epitopes on the spike receptor binding domain (RBD) of SARS-CoV-2. Here we report the isolation, characterization and recombinant production of 12 neutralizing human mAbs, targeting three distinct epitopes on the spike N-terminal domain (NTD) of the virus. Neutralization mechanism of these antibodies involves receptors other than the canonical hACE2 on target cells, relying both on amino-acid and N-glycan epitope-recognition, suggesting alternative viral cellular-portals. Two selected mAbs demonstrated full protection of K18-hACE2 transgenic mice when administered at low doses and late post-exposure, demonstrating the high potential of the mAbs for therapy of SARS-CoV-2 infection.

The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inflicted an enormous public health and economic crisis and continues to spread globally. Despite the recent onset of mass vaccination campaigns, the pandemic exhibits unprecedented extent of morbidity and mortality. Consequently, there is still an urgent need for effective therapeutics. The virus spike (S) glycoprotein, essential for the recognition of its human cognate angiotensin-converting enzyme 2 (hACE2) receptor on target cells and subsequent viral internalization, was implicated as the main target for coronavirus neutralizing monoclonal antibodies (mAbs). Processing of the S protein by host proteases results in the generation of the S1 subunit, responsible for receptor engagement and the S2 subunit which mediates membrane fusion (Hoffmann et al., 2020) . Two functional domains can be distinguished within the S1 subunit: the Nterminal domain (NTD) and the C-terminal domain (CTD) (Walls et al., 2020) . SARS-CoV-2, similar to SARS-CoV, uses CTD as the receptor binding domain (RBD), associated with direct contact to the hACE2 receptor (Shang et al., 2020b; Wrapp et al., 2020) . However, some other betacoronaviruses use the NTD of their S1 subunit to bind various host cell receptors. For example, the HCoV-OC43 and HCoV-HKU1 respective NTDs recognize terminal 9-O-acetylated sialic acid moieties of glycosylated cell-surface receptors (Fung and Liu, 2019; Huang et al., 2015; Tortorici et al., 2019) . Similarly, the betacoronavirus murine hepatitis virus uses its NTD for binding the protein receptor CEACAM1 (Shang et al., 2020a) and MERS-CoV utilizes a dual-receptor strategy, using both protein (DPP4) and sialoside receptors to infect host cells (Fung and Liu, 2019; Park et al., 2019) . The role of the NTD of SARS-CoV-2 is yet to be fully understood, but accumulating evidence suggests that it is important for SARS-CoV-2 infectivity.

Comparison of the NTD primary sequences and spatial architectures of SARS-CoV, MERS-CoV and SARS-CoV-2, reveals several loop regions common to both SARS-CoV-2 and MERS-CoV but lacking in SARS-CoV (Awasthi et al., 2020) . These loops constitute a potential sialoside binding pocket and therefore may use human sialosides as an alternate receptors for SARS-CoV-2 infection in a variety of tissues. Moreover, L-SIGN and DC-SIGN, members of the C-type lectin superfamily, were recently suggested as possible alternative receptors for SARS-CoV-2, via interaction with the NTD domain J o u r n a l P r e -p r o o f (Amraei et al., 2020; Gao et al., 2020; Soh et al., 2020) . Theoretically, the wide repertoire of human tissues and immune cells expressing these receptors, may explain the presence of SARS-CoV-2 in many tissues of the infected host which do not exhibit significant or even detectable ACE2 expression levels.

Direct interference of the SARS-CoV-2 engagement with its ACE2 cognate receptor on target cells, represents the main mechanism of virus neutralization, exhibited by most of the reported therapeutic antibodies developed for COVID-19 treatment. Accordingly, these antibodies were identified on the basis of their ability to bind RBD, some of which present substantial neutralization efficiencies Cao et al., 2020; Ju et al., 2020; Liu et al., 2020; Noy-Porat et al., 2020; Rosenfeld et al., 2021) . Nevertheless, one of the major concerns when using therapeutic anti-viral antibodies is the emergence of escape-variants, due to the rapid mutation frequency of viral pathogens and the selective pressure imposed upon one defined domain by a single mAb, recognizing one particular epitope. One of the most effective ways to circumvent this therapeutic complication is treatment with mAbs directed to different epitopes. Indeed, administration of mAbs combination was shown to efficiently reduce the development of antibody resistance in the case of HIV infection (Awi and Teow, 2018) and also in the case of SARS-CoV-2 . Therefore, development of neutralizing mAbs targeting diverse epitopes on the S glycoprotein represents a high priority objective.

So far, only few reports documented isolation of NTD-specific human mAbs (Brouwer et al., 2020; Chi et al., 2020; Jiang et al., 2020; Liu et al., 2020; Suryadevara et al., 2021) .

The mechanism of neutralization promoted by anti-NTD mAbs is not fully understood and in general, these reported antibodies exhibited inferior neutralizing capabilities compared to RBD-specific mAbs. However, it seems that the spike NTD represents also an important element involved in SARS-CoV-2 infectivity, and therefore, a possible additional target for neutralizing antibodies. The recent emergence of escape variants further encouraged consideration of neutralizing mAbs against NTD as a therapeutic strategy, possibly in combination with anti-RBD mAbs.

J o u r n a l P r e -p r o o f Accordingly, the objective of the study reported here was isolation of potent neutralizing anti-NTD mAbs, by a phage-display approach, using libraries constructed from lymphocytes collected from human severe COVID-19 patients.

Blood samples obtained from seven severe COVID-19 patients, were quantitatively evaluated by determining the antibody titers against S1 (by ELISA) and viral neutralization activities (by plaque reduction neutralization test, PRNT). The presence of anti-S1 antibodies (titers >10,000), as well as high neutralization potency (titers>1,000), were confirmed in all serum samples ( Figure S1 ). In light of their high neutralization titers and in order to obtain a diverse antibody library, all seven samples were combined for the purpose of antibody library construction.

A phage-display single chain Fv (scFv) library, consisting of 1.3x10 9 distinct clones was constructed for the subsequent antibody isolation. Three enrichment steps of panning were carried out by allowing the binding of phages to monomeric NTD, followed by screening of individual clones. ELISA of 400 individual clones from the 3 rd cycle, for NTD or RBD binding, resulted in the identification of >300 (75%) clones specific for NTD binding. One hundred and forty (140) clones were further examined by restriction fragment size polymorphism (RFLP), allowing identification of 19 unique patterns indicative of diverse sequences. Following DNA sequencing of clones representing these diverse patterns, 12 scFvs, showing sequence diversity ( Figure S2 ), were expressed as scFv-Fc antibodies for further characterization. Sequence analysis was performed to the 12 mAbs, using IgBlast (Ye et al., 2013) , and germline families were assigned for each of the mAbs (Table 1) .

The most prevalent V gene distinguished in the sequence of the mAbs was IGHV1-24, previously reported to be significantly enriched in anti-SARS-CoV-2 antibodies (Brouwer et al., 2020) . This germline family was also shown to be significantly enriched in expanded IgG+ B cell clones of COVID-19 patients, suggesting preferential recruitment and viral epitope binding by B cells exhibiting antigen receptors involving this IGHV allele (Nielsen et al., 2020) . Interestingly, BLN14 exhibited sequences originating from germline families IGHV3-30, IGKV3-20 and IGHJ6, which were J o u r n a l P r e -p r o o f previously shown to be over-represented in anti-SARS-CoV-2 mAbs . This is especially notable considering that the combination of VH and VL did not originate in the context of the humoral immune response of the exposed individuals, but was rather the result of combinatorial pairing of heavy and light chains during library construction. This observation implies that combination of these particular germline families which was favorably selected in the course of screening, may preferentially generate antibodies exhibiting high affinity against SARS-CoV-2, as previously suggested (Kreer et al., 2020; Liu et al., 2020) .

All 12 mAbs exhibited a relatively long CDRH3 loop (an average of 18 amino acids compared to an average of 13 for human antibodies (Zemlin et al., 2003) ), a characteristic which was observed for many anti-SARS-CoV-2 mAbs, and in particular of non-RBD neutralizing antibodies (Brouwer et al., 2020; Liu et al., 2020; Nielsen et al., 2020) . In addition, the mAbs selected here reveal low levels of IGHV somatic hypermutations (SHM), 8 out of 12 exhibiting 5 or less mutations in their DNA sequence, and all twelve inspected exhibiting an average of 5.8 ± 2.9. These SHM levels account for less than 5% difference in sequence compared to germline. This phenomenon was also observed in many SARS-CoV-2 mAbs and IgG+ B cell clones derived from COVID-19 patients (Brouwer et al., 2020; Nielsen et al., 2020) . This low level of SHM was shown to increase over time only at a moderate frequency (Kreer et al., 2020) , indicating that the mutations level is independent of the time of isolation after the onset of the disease. The number of DNA-SHM was higher and more diverse in the IGLV genes (average of 9.7 ± 5.8; 1-8% difference from germline), suggesting that this portion of the antibodies is subjected to a reduced level of selection constrains. ranged from 0.7 nM to 34 nM, BLN1 and BLN12 showing the highest affinity and BLN4, the lowest.

The neutralization potency of the antibodies was evaluated by plaque reduction neutralization test (PRNT) using VeroE6 cells infected with authentic SARS-CoV-2.

Accordingly, a fixed amount of the virus was incubated with increasing concentrations of each antibody, the mixture was then added to the cells, and the half-maximum inhibitory concentration (IC 50 ) was determined 48 h later ( Figure 1B ) . All 12 antibodies were found to efficiently neutralize the virus, exhibiting IC 50 values ranging from 54.9 µg/ml for BLN8, to a highly potent values of 0.008 µg/ml for mAbs BLN1 and BLN12 (Table S1 ).

The panel of antibodies was classified into clusters, representing competitive epitope recognition, as determined by BLI epitope binning assays ( Figure 2 ). Each individual antibody was biotinylated, immobilized to a streptavidin sensor, loaded with S1 and then competed with each of the other antibodies. The ability of two antibodies to bind S1 concomitantly (as identified by a wavelength shift in the interference pattern), indicates that they bind non-overlapping distinct epitopes . Of note, the inability of two antibodies to bind together (competing antibodies) does not necessarily indicate that they bind the same epitope, as their competition may suggest steric interference due to binding to adjacent epitopes. Thus, the assay allows classification of antibody binding sites on the S1 subunit, based on the proximity of their respective epitopes. A representative example, showing sensograms of the 12 mAbs interactions with the pre-complex BLN12-S1, is depicted in Figure 2A . As shown, antibodies BLN4, BLN6 and BLN8 recognize epitopes distinct from those recognized by BLN12, as manifested by a marked wavelength shift. However, all other antibodies did not elicit any marked shift in the presence of BLN12, indicating that they target overlapping or close epitopes. The ability of each antibody pair to simultaneously bind S1 was next determined for all the 11 other antibodies ( Figure 2B -binning matrix; Figure S5 ). In summary, the 12 anti-NTD antibodies could be classified into three groups, based on recognition of three distinct epitopes. Group I includes BLN8, Group II includes BLN4 and BLN6 and Group III includes all other antibodies ( Figure 2C ).

Of note, the antibodies in group III (9 out of 12 mAbs), exhibited the highest neutralization potency compared to mAbs belonging to groups I and II, suggesting that the domain recognized by these antibodies, represents a major site of vulnerability of the SARS-CoV-2 and therefor a potential target for its neutralization.

In an attempt to further characterize the mAb specific recognition sites, representative members of the three groups were selected and subjected to epitope mapping, employing an array of overlapping synthetic peptides derived from the entire S1 protein. This strategy inherently enables only identification of linear epitopes, recognized by an antibody, therefore recognition of conformational epitopes which is often exhibited by neutralizing antibodies, cannot be detected. Indeed, mAbs BLN14 and BLN8 did not bind any of the peptides in the array. On the other hand, mAbs BLN4 and BLN12 were found to bind specific peptides, resulting in the identification of their recognition epitopes. The peptide recognized by BLN4 spans amino acids 56-65 (LPFFSNVTWF) of the spike protein (according to GenPept QHD43416 ORF) and the peptide recognized by BLN12 spans amino acids 141-155 (LGVYYHKNNKSWMES). The position of both mAbs on the spike structure is visualized in Figure 2D -E. Notably, the identified peptide, found to be recognized by mAb BLN12, resides within the NTD N3 loop that was recently reported to be recognized by mAb 4A8, as determined by resolved structure of the 4A8 in complex with the SARS-CoV-2 spike (Chi et al., 2020) . In order to confirm the location of BLN12 epitope, a recombinant in-house version of 4A8 was generated and examined in an epitope binning assay together with the selected set of mAbs ( Figure 2F ). Each of the selected mAbs was immobilized on a streptavidin sensor, loaded with NTD and further challenged with 4A8. Antibody 4A8 was indeed found to compete with mAbs BLN12 and BLN14, belonging to Group III. This competition further confirms BLN12 recognition site and reinforce the previous observation indicating an adjacent epitope for BLN14 as well. Interestingly, both BLN4 and BLN12 recognition sites, include Nglycosylation sites, located at residues N61 and N149 of the S protein, respectively (Watanabe et al., 2020) . Recognition of the synthetic peptides may imply that glycosylation (or other post-translational modifications) are not crucial for the binding of these epitopes by the antibodies, yet the presence of the glycosylation signals encouraged inspection of glycans impact on the mAb interaction with the NTD. SARS-CoV-2 spike J o u r n a l P r e -p r o o f protein have been shown to express diverse N-glycans, including oligo-mannose and sialic acid-containing hybrid/complex-N-glycans (Watanabe et al., 2020) . Therefore, the four antibodies, representing the three groups, were examined on an exhaustive nanoprinted glycan microarray, in which individual glycans are covalently immobilized via a primary amine linker onto an epoxide-coated glass slide. The glycan library contained a wide collection of glycans with terminal sialic acid (Sia), non-sialylated glycans (non-Sia) (Padler-Karavani et al., 2012) , and a collection of homo-and heteroglycodendrons of mono/oligo-mannose and -galactose ligands (Man) (Gade et al., 2018) ( Figure S6 ). While there was very low binding to most examined glycans, the antibodies revealed a strong preference to the N-glycans-associated structures LNT-3Ac (Glycan ID #60; Neu5Ac3Galβ3GlcNAcβ3Galβ4GlcβOR) and LNT (Glycan ID #59; Galβ3GlcNAcβ3Galβ4GlcβOR) ( Figure S6 ). However, binding was not detected when the terminal sialic acid was replaced with Neu5Gc (N-glycolylneuraminic acid), the hydroxylated form of Neu5Ac (LNT-3Gc; Glycan ID #61;

Neu5Gc3Galβ3GlcNAcβ3Galβ4GlcβO-R) ( Figure S6 ). To further investigate these interactions, the antibodies were subjected to a competition assay assessing inhibition of antibodies binding to NTD, using glucuronic acid (GlcA), Neu5Ac in its closed ring - Both GlcA and Ac2Me showed no inhibition of antibodies binding, however the Neu5Ac-sialoglycopeptides completely abrogated binding of BLN4 and BLN12, but not that of BLN8 and BLN14 ( Figure 3A ), suggesting that the interactions with the N-glycans are involved in the binding to NTD of BLN4 and BLN12 in particular.

These results are in-line with the epitope mapping data and collectively suggest that BLN4 and BLN12 recognize both the amino-acid sequences and the glycan moieties appended to their cognate respective epitopes on NTD.

To address the mechanism underlining the neutralization characteristics of the anti-NTD mAbs, a hACE2 binding inhibition assay was conducted, as blockage of the hACE2 J o u r n a l P r e -p r o o f receptor engagement is considered to represent the most effective virus neutralization mechanism of anti-RBD mAbs. Thus, biotinylated-BLN antibodies were immobilized on streptavidin sensors and their ability to inhibit S1 binding to hACE2 was tested by BLI ( Figure 3B ). A wavelength shift indicates binding of hACE2 to mAb-S1 complex and hence, lack of inhibition by the mAb tested. Four mAbs, representing the three epitope groups were examined. The anti-RBD antibodies MD65, previously demonstrated to inhibit hACE2 binding, and MD29 which does not inhibit hACE2 binding (Noy-Porat et al., 2020) , were used as positive and negative controls, respectively.

Results indicate that, as anticipated, none of the tested anti-NTD mAbs inhibits hACE2

binding. It may therefore be confirmed that the neutralization mechanism promoted by these antibodies does not involve the inhibition of hACE2 binding.

It was recently reported that in addition to the "canonical" ACE2 receptor binding by RBD, SARS-CoV-2 NTD interacts with C-type lectin receptors, including L-SIGN and DC-SIGN (Gao et al., 2020; Soh et al., 2020) as an alternative route for SARS-CoV-2 infection and entry into host cells. Accordingly, the ability of four representative anti-NTD mAbs (which bind different epitopes on the NTD) to inhibit the interaction of the NTD with L-SIGN, was examined ( Figure 3C -D). Binding of NTD to L-SIGN was first evaluated in comparison to RBD using BLI. Indeed the NTD was found to interact with L-SIGN, while RBD showed only low level of interaction, as also reported previously (Amraei et al., 2020; Soh et al., 2020) ( Figure 3C ). This interaction, was then evaluated in the presence of selected anti-NTD mAbs ( Figure 3D ), showing partial inhibition, ranging from approximately 25% binding inhibition by BLN14 to 50% inhibition by BLN4. We may therefore conclude that neutralization promoted by the anti-NTD antibodies partially involves interference with the binding of L-SIGN receptor and that additional entities or functions may be involved. It should be noted, that the observed binding inhibition may be the result of steric interference of L-SIGN binding to NTD, and not necessarily direct blocking of the NTD glycans, involved in binding to L-SIGN.

For in vivo assessment of the therapeutic potential of the antibodies, the anti-NTD BLN12 and BLN14 were selected. Antibody BLN12 was superior to the other antibodies in the panel, in terms of affinity (0.9 nM) and in vitro neutralization potency (IC 50 =8 ng/ml). Although antibody BLN14 exhibited lower affinity (12.7 nM) than others, it revealed relatively high in vitro neutralization (IC 50 =30 ng/ml) and its sequence differed from that of BLN12 (Table S1 ; Table 1 ). Antibodies BLN12 and BLN14 were therefore examined for their ability to protect K18-hACE2 transgenic mice from an authentic SARS-CoV-2 infection in vivo. The K18-hACE2 transgenic murine model was shown to be highly susceptible to SARS-CoV-2 infection, resulting in significant viral load in the lungs, heart, brain and spleen, as well as high mortality (Winkler et al., 2020; Yinda et al., 2021; Zheng et al., 2021) . This model was recently shown to fatefully recapitulate the SARS-CoV-2 infection and consequently to serve as a reliable model to predict the efficacy of therapeutic strategies (Golden et al., 2020; Jia et al., 2020; Winkler et al., 2020; Zheng et al., 2021) . In a recent study, we applied this model for demonstration of the protection efficacy of therapeutic mAb directed to the S1-RBD, when administered 2 days post-infection (dpi) (Rosenfeld et al., 2021) .

For the in vivo experiments, BLN12 and BLN14 were produced as full recombinant IgG molecule of the IgG1/k isotype which includes the triple-mutation M252Y/S254T/T256E (YTE) in the Fc region. These modifications are intended to prolong the antibodies serum half-life in humans (by increasing their affinity towards the human FcRn), a parameter that is essential for high therapeutic value (Gaudinski et al., 2018; Oganesyan et al., 2014; Yu et al., 2017) . However, these mutations are not predicted to have any effect in a murine-model, due to cross-species differences in FcRn-IgG interactions.

K18-hACE2 transgenic mice were infected intranasally (IN) with 300 pfu/mouse SARS-CoV-2, resulting in more than 75% mortality within 7-10 days following infection. Based on the superior in vitro neutralization ability of the BLN12 and BLN14 anti-NTD mAbs, the in vivo potency of these two mAbs was directly tested at a stringent model of 2 dpi. 

Administration of antibodies enables efficient therapy both by neutralization of the pathogen, as well as by extending the time window necessary for the mounting of an endogenous host response. Therefore, elicitation of an endogenous humoral response following passive immunization, represents a significant advantage of mAb treatment, especially in case where re-infection is a tangible possibility, as in the case of the SARS-CoV-2 pandemic. Hence, the murine humoral response against SARS-CoV-2 related antigens was measured in BLN12-and BLN14-treated mice ( Figure 4C ). Serum samples were collected 21 dpi following post-exposure (2 dpi) administration of each mAb, at dose of 0.1 or 0.01 mg per animal. The murine antibody response was tested by ELISA against SARS-CoV-2 spike glycoprotein, RBD and NTD ( Figure 4C ). Note that in this timepoint, no excess of the human mAb, used for treatment, could be detected ( Figure   S7 ). All treated mice revealed elicitation of immune responses against the three tested antigens. This result is in a good agreement with our previous observation, using anti-RBD mAb (Rosenfeld et al., 2021) . In this previous report, endogenous response, following treatment with high mAb dose, was shown to correlate with time of treatment, demonstrating a marked response in post-exposure treatment, rather than in prophylactic one. In the current study, by evaluating the 2 doses of mAb treatment at 2 dpi, a J o u r n a l P r e -p r o o f significant endogenous response is demonstrated ( Figure 4C ). Furthermore, this antibody response was demonstrated to consist of significant neutralizing activity, as was demonstrated by applying PRNT ( Figure 4D ).

The continuing escalation of the COVID-19 pandemic, complicated by the recent emergence of SARS-CoV-2 variants, motivate the development of efficient means for therapeutic intervention. Here we described the isolation of a panel of novel recombinant human mAbs, targeting the SARS-CoV-2 NTD domain originating from libraries constructed with antibodies collected from COVID-19 active patients. The germline usage, epitope specificities, binding characteristics and neutralizing abilities of 12 antibodies were determined; subsequent assessment of two of them in vivo revealed exceptional potency promoting full protection of lethally infected mice and suggesting that they may serve as promising candidates for antibody-mediated therapy. It is conceivable that in combination with anti-RBD mAbs, therapeutic administration of these antibodies may contribute to avoid complications related to the occurrence of viral escape mutants which may not be neutralized by targeting only one particular epitope.

Germline usage analysis of the 12 mAbs isolated in the current study, determined high preference for germline genes also observed for other SARS-Cov-2 antibodies (Brouwer et al., 2020; Liu et al., 2020) . Dominant germlines in antibodies targeting RBD were previously reported (Yuan et al., 2020) therefore the present data imply that similar dominant germlines are used for generation of anti-NTD antibodies as well. The anti-NTD mAbs exhibited low numbers of somatic mutations, similarly to anti-RBD mAbs, and the frequency of somatic mutations could not be correlated to neutralization potency or to a certain epitope, suggesting that they did not occur as a result of selection for high antigen affinity. Interestingly, anti-RBD mAbs were shown to possess a relatively short CDRH3, while most anti-NTD mAbs display a significantly longer CDRH3, a difference which probably reflects the dissimilar nature of the epitopes: while anti-RBD antibodies recognize surface epitopes, the NTD epitopes reside within a large pocket in the spatial architecture of the S1 molecule, to which antibodies exhibiting longer CDRH3 loops may preferentially bind efficiently. Of note, BLN8, representing a unique epitope amongst the novel mAbs, was the only one displaying a relatively short CDRH3. These observations are in line with those recently reported by Yuan et al. (Yuan et al., 2020) showing that a short CDRH3 represents a characteristic molecular features common to the antibody J o u r n a l P r e -p r o o f response to SARS-CoV-2 RBD, possibly owing to the fact that the specific epitopes recognized by these antibodies are relatively flat.

Many viruses, including HIV-1 (Wagh et al., 2020; Ward and Wilson, 2017) and SARS-CoV-2 (Watanabe et al., 2020) , display a strong glycan shield as they bud out of the infected host cells, possibly as a host cell mimicking mechanism, for evading the immune system. It has been shown that some of the most potent neutralizing antibodies against HIV-1 target this glycan shield (Ward and Wilson, 2017), not by recognizing a shallow groove within a binding pocket, but rather by a mechanism allowing for such antibodies to be "embraced" by extended glycan chains. In particular, the PG9 antibody is uniquely characterized by an unusually long CDRH3 loop of its heavy chain forming a hammerhead-like structure accommodated by two N-glycan arms extending out from the viral gp120 trimer (within the highly variable V1/V2 domain). This phenomenon contributes to the stabilization of the interaction between the gp120 trimer and the antibody facilitating neutralization of the virus (McLellan et al., 2011; Sattentau, 2011) .

Here we show that some of the SARS-CoV-2 neutralizing antibodies characterized by a long CDR3 (i.e. BLN4, BLN12), similarly interact with extended N-glycan structures of NTD.

One of the important aspects of the antibodies presented here is that they neutralize the SARS-CoV-2 virus by a mechanism which does not involve interference with engagement of the ACE2 receptor, therefore their potency underlines the importance of alternative modality employed by the virus primary interaction with the target host cell at the onset of infection. Although SARS-CoV-2 mainly infects the lungs, it also targets multiple other organs including the cardiovascular system, gastrointestinal tract, and kidneys (Ackermann et al., 2020; Rahimi, 2020; Wiersinga et al., 2020) , tissues where hACE2 expression is very low or undetectable, implying such an alternative infection route. The C-type lectin family is one of the largest subgroup of the lectin superfamily. (Guan et al., 2020; Liao et al., 2020) . The densely glycosylated SARS-CoV-2 spike protein was recently shown to directly interact with a variety of lectin receptors, such as DC-SIGN and L-SIGN, suggesting an alternative route for SARS-CoV-2 viral entry (Amraei et al., 2020; Gao et al., 2020; Soh et al., 2020) .

Epitopes recognized by BLN12 and BLN14 were mapped to the same cluster, by the binning experiments, yet it was clearly demonstrated that they do not share exactly the same epitope. We show that while BLN12 identifies glycans as part of its epitope, BLN14 does not. Both antibodies also differ in their ability to bind linear epitopes and slightly differed in their capability to inhibit NTD binding to L-SIGN. Nevertheless, as explained, the epitopes recognized by these two antibodies are expected to be proximal.

The two mAbs exhibited similar in vitro and in vivo neutralization capabilities. It is conceivable therefore to assume that their neutralization mechanism is very similar.

Glycans on N149 of NTD were suggested to mainly mediate the interaction with L-SIGN, while N-glycosylation in positions N74 and N282 may have a partial role in such interaction (Soh et al., 2020) . Epitope mapping data pointed to N149 as a part of BLN12 epitope, and glycan inhibition assay confirmed the presence of glycans within this mAb In conclusion, the 12 mAbs reported here, recognized three distinct epitopes within the spike-NTD. Two of these epitopes, represented by BLN4 and BLN8, seem to be less important for the virus neutralization. The third epitope, however, was found to be a major point of vulnerability for the virus. Antibodies BLN12 and BLN14, directed to this epitope, and characterized in this study, showed remarkable neutralization of the authentic SARS-CoV-2 in vitro and more importantly, allowed full protection in an animal model of lethal infection, even when administered at a low dose (0.5 mg/Kg) and at a late time point after infection (2 dpi). Notably, although the high susceptibility of the K18 transgenic mouse model to SARS-CoV-2 infection is associated with the hACE2 expression, treatment with NTD specific mAbs (that are not interrupting with the hACE2 J o u r n a l P r e -p r o o f interaction), resulted in equivalent protection efficacy, observed by the potent RBD specific mAb MD65, as reported lately (Rosenfeld et al., 2021) . This observation further emphasize the complementary protection efficacy of NTD-specific mAbs .The BLN12

and BLN14 mAbs, reported herein therefore, represent excellent candidates for therapy of SARS-CoV-2, possibly in combination with anti-RBD mAbs.

All in vivo experiments in this study were conducted using transgenic K18-hACE2 mice.

Therefore, the potential of the antibodies described in the article for therapeutic use in humans will have to be further evaluated.

We 

Patent application for the described antibodies was filed by the Israel Institute for Biological Research. None of the authors declared any additional competing interests. Binding specificity and neutralization profiles of 12 selected anti-NTD mAbs (referred to as BLN1-BLN14). A. The specificity of each mAb was tested by ELISA using either SARS-CoV-2 S, NTD, RBD or S1 purified recombinant proteins as capturing antigens, as indicated by different colors. Data represent individuals and average of triplicates ±SEM. Binding intensity depends on molarity, availability and number of binding sites per antigen. Normalized data is presented in Figure S3 . Table S1 .

Biolayer interferometry (BLI). Each purified antibody was biotinylated, immobilized on a streptavidin sensor and loaded with S1. The complex (mAb-S1) was then incubated for 300 s with each one of the other antibodies. Distinct epitope recognition was evaluated by the ability of each pair of antibodies to simultaneously bind S1. A.

Representative BLI results are depicted for the BLN12 mAb. Time 0 represents the binding to the BLN12-S1 complex by each of the indicated antibodies. Competition with antibody BLN12 itself served as a negative control, subtracted from the data before generation of the depicted sensograms. Detailed competition profiles obtained with all 12 antibodies are presented in Figure S5 . DNA sequences of the antibodies were analyzed by IgBlast, for determining the germline allele usage and CDR3 loop length (Ye et al., 2013) . See Figure S2 for full amino acid sequences. Each tested mAb was biotinylated, immobilized on a streptavidin sensor and interacted with increasing amounts of NTD. Binding kinetics curves were fitted using the 1:1 binding model (see Figure S4 ).

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ohad Mazor from the Israel Institute for Biological

Research; ohadm@iibr.gov.il.

Antibodies are available for research purposes only under an MTA, which allows the use of the antibodies for non-commercial purposes but not their disclosure to third parties.

All other data are available from the Lead contact upon reasonable requests.

The published article includes all dataset generated or analyzed during this study.

Anonymized surplus blood samples of COVID19 patients with persistent critical illness >21 days after first day of symptom onset and taken as part of routine care (St Thomas' Hospital, London, UK) were retrieved at the point of being discarded. Work was undertaken in accordance with UK Research Ethics Committee (REC) approval for laboratory research projects investigating the immune response to COVID-19 infection with academic collaborators (REC reference 20/SC/0310). Samples were treated in accordance with the biosafety guidelines of the IIBR in BL3 facility. PBMCs were separated from fresh whole blood using density centrifugation by Ficoll. Sera samples were heat-inactivated (20 min at 60°C) prior to use for binding or neutralizing assays. 

Vero E6 (ATCC® CRL-1586 TM ) were obtained from the American Type Culture

Collection. Cells were grown in Dulbecco's modified Eagle's medium (DMEM)

supplemented with 10% fetal bovine serum (FBS), MEM non-essential amino acids (NEAA), 2 mM L-glutamine, 100 Units/ml penicillin, 0.1 mg/ml streptomycin and 12.5

Units/ml Nystatin (P/S/N) (Biological Industries, Israel). Cells were cultured at 37°C, 5%

CO 2 at 95% air atmosphere.

ExpiCHO-S (Thermoscientific, USA, Cat# A29127) were used for expression of recombinant proteins as described above.

SARS-CoV-2 (GISAID accession EPI_ISL_406862) was kindly provided by (Finkel et al., 2020) .

Handling and working with SARS-CoV-2 was conducted in BL3 facility in accordance with the biosafety guidelines of the IIBR.

J o u r n a l P r e -p r o o f

Cultures were grown in YPD supplemented with 100 µg/ml ampicillin and 1% glucose, at 30°C.

The SARS-CoV-2 spike (S) stabilized soluble ectodomain, S1 subunit, N-terminal domain (NTD), receptor binding domain (RBD) and the human angiotensin-converting enzyme 2 (hACE2) were produced as previously described (Noy-Porat et al., 2020) .

Briefly, mammalian cell codon optimized nucleic sequence, coding for SARS-CoV-2 spike glycoprotein (GenPept: QHD43416 ORF), was used to design pcDNA3.1+ based expression plasmids, mediating recombinant expression of the entire spike glycoprotein (amino acids 1-1207), RBD (amino acids 1-15 and 318-542), NTD (amino acids 1-305) and S1 (amino acids 1-685). C-terminal his-tag as well as streptag, was included in all constructs in order to facilitate protein purification. Expression of the recombinant proteins was performed using ExpiCHO TM Expression system (Thermoscientific, USA)

following purification using HisTrap TM (GE Healthcare, UK) and Strep-Tactin ® XT (IBA, Germany). The same expression vector was utilized for cloning and production of the secreted form of the hACE2 receptor (amino acids 1-740; GenPept: NP_068576.1 ORF).

L-SIGN-hFc tag was purchased from R&D systems (USA). Antibody 4A8 was produced in-house according to GenBank accession no. MT622682/3.

Total RNA was purified from PBMCs using RNeasy mini kit (Qiagen GmbH, Germany) and used for cDNA synthesis (Verso cDNA synthesis kit; Thermoscientific, USA).

Antibodies variable region coding fragments were amplified directly from cDNA, using a human V/J specific set of primers (Noy-Porat et al., 2020) . Phage-display library was Phage particles were pelleted by centrifugation (9000 g at 4 °C for 1 h) and re-dissolved in 5 ml Dulbecco's Phosphate Buffered Saline (PBS; Biological Industries, Israel).

Panning was performed against monomeric NTD directly absorbed to polystyrene plates (Maxisorb 96-well microtiter plates; Nunc, Sigma-Aldrich, USA). Blocking of plates and phages was conducted for 60 min using two blocking solutions: 3% BSA (in PBS) or 2% skimmed milk and 0.05% Tween20 in PBS. The blocking solutions were alternated between panning cycles. All washing steps were performed using PBST (PBS containing 0.05% Tween20 and 2% BSA). For each panning cycle, 5 µg/ml antigen was used to coat the polystyrene plate and after an overnight incubation, plates were washed and blocked.

For the first panning cycle, approximately 1x10 11 phages were incubated with the antigen coated plates for 60 min, followed by a total of 3 washes with PBST. Phages were eluted by incubation with 1ml of 100 mM Triethylamine (Sigma, Israel) for 30 min and following neutralization (in 200 µl 1M Tris-HCl, pH=7.4), were used to infect 5 ml of E.

coli TG1 strain, by incubation at 37°C for 30 min without shaking followed by 30 min at 120 rpm. The bacterial culture was plated on YPD-Amp-Glu agar, and incubated overnight at 30°C. Clones were harvested into 5 ml YPD-Amp-Glu with 20% glycerol solution and phage production for the next round of panning was conducted in 10 ml medium, as described above. Two additional panning cycles were conducted essentially J o u r n a l P r e -p r o o f similarly, with the following modifications: 10 10 phages were used as input for the 2 nd and 3 rd cycles, and the washing steps were increased to include 6 washes of PBST.

Single colonies were randomly picked from the third cycle output and screen of specific binders was performed, using phage ELISA against NTD Vs RBD.

TAB-RI_For (CCATGATTACGCCAAGCTTTGGAGCC) and CBD-AS_Rev (GAATTC AACCTTCAAATTGCC) phagemid specific primers were used for colony PCR and sequence analysis of scFv antibody individual clones. Colony PCR products, were analyzed on 1.5 % agarose gel, to confirm the intact of the scFv. Restriction fragment size polymorphism (RFLP), was performed using MvaI (FastDigest;

Thermoscientific, USA) to evaluate sequence variability of scFv individual clones.

Following colony PCR, 5µl of the PCR products were taken directly for restriction with 0.5 µl MvaI and 1 µl buffer x10 (provided by the manufacturer) in a 10 µl reaction volume. Restriction was conducted for one h at 37C, and the entire reaction mix was then resolved on 3% agarose gel. Nucleic acid sequence analysis of individual scFv fragments, was performed to the colony PCR product, using SeqStudio Genetic Analyzer (Applied Biosystems, USA).

J o u r n a l P r e -p r o o f The endogenous humoral response was tested in mice sera samples collected at 21 days post infection (dpi), evaluated by ELISA against SARS-CoV-2 spike, NTD and RBD essentially as described above, using AP-conjugated Donkey anti-mouse IgG (H+L) minimal cross (Jackson ImmunoResearch, USA, Cat# 715-055-150, lot 142717) used at 1:2,000. ELISA was also performed on the same sera samples, using AP-conjugated Donkey anti-human IgG, to confirm there is no residual human antibodies, used as treatment.

Binding studies were carried out using the Octet system (ForteBio, USA, Version 8.1, 2015) that measures biolayer interferometry (BLI). All steps were performed at 30°C

with shaking at 1500 rpm in a black 96-well plate containing 200 μl solution in each well.

Streptavidin-coated biosensors were loaded with biotinylated antibody (5-10 µg/ml) to reach 1 nm wavelength shift followed by a wash. The sensors were then reacted for 300 s with increasing concentrations of monomeric NTD (association phase) and then transferred to buffer-containing wells for another 600 s (dissociation phase). Binding and dissociation were measured as changes over time in light interference after subtraction of parallel measurements from unloaded biosensors. Sensorgrams were fitted with a 1:1 binding model ( Figure S4 ) using the Octet data analysis software 8.1 (Fortebio, USA, 2015) .

For the binning experiments of antibodies pairs, antibody-loaded sensors were incubated with a fixed concentration of S1 (20 µg/ml), washed and incubated with the non-labeled antibody counterpart. In each set of experiments, the background signal was obtained from a parallel sensor incubated with the homologous antibody and sensograms are presented after subtraction of the background signal ( Figure S5 ).

To study the binding of hACE2 to S1 in the presence of antibodies, antibody-loaded sensors were incubated with S1, washed and incubated with hACE2 (10g/ml).

In order to study the interaction of L-SIGN with NTD, L-SIGN was immobilized on Protein A sensors and allowed to bind NTD or RBD in binding buffer (50mM Hepes, 5 mM CaCl 2 , 5 mM MgCl 2 ).

For L-SIGN binding inhibition assay, NTD-His (10 µg/ml) was immobilized on Ni-NTA sensors, incubated with anti-NTD antibodies washed and incubated with L-SIGN (20 µg/ml). No Ab signal was obtained from sensor incubated with L-SIGN without the presence of antibodies and background signal was obtained from a parallel sensor incubated with L-SIGN without the presence of NTD and sensograms are presented after subtraction of the background signal.

Lyophilized 240 biotinylated 15 amino-acid long peptides (with 10 amino-acid overlap)

covering the entire ectodomain of SARS-CoV2 spike protein were purchased from JPT (Germany). All peptides were re-suspended in di-methyl sulfoxide (DMSO) to a concentration of 1 mg/ml, aliquoted and stored at -20ºC. An aliquot of the peptides was thawed, diluted 1:100 in 1xPBS (to reach 10 µg/ml) and added to Maxisorp ELISA plates (Thermoscientific) pre-coated with streptavidin and blocked with 2% Bovine serum albumin (BSA). Plated peptides were incubated with the individual monoclonal antibodies (5 µg/ml diluted in blocking buffer) and further incubated with donkey antihuman alkaline phosphatase-conjugated secondary antibody (Jackson ImmunoResearch, USA). Immune complexes were identified following incubation with SIGMAFAST™ PNPP (SIGMA) and measuring absorbance at 405 nm. For the modeling of mAbs recognition sites on SARS-CoV-2 S protein, spike structure with PDB ID 7C2L (Chi et al., 2020) AlexaFlour-555-Hydraside (Invitrogen, at 1 ng/µl in 178 mM phosphate buffer, pH 5.5)

were used for each printing run. The humidity level in the arraying chamber was maintained at about 70% during printing. Printed slides were left on an arrayer deck overnight, allowing humidity to drop to ambient levels (40-45%). Next, slides were packed, vacuum-sealed, and stored at room temperature (RT) until used.

Slides were developed and analyzed as described ( 

For plaque reduction neutralization test (PRNT) (Eyal et al., 2005) , Vero E6 cells were seeded overnight (as detailed above) at a density of 0.5e6 cells/well in 12-well plates.

Antibody samples were 2-fold serially diluted (ranging from 100 to 0.78 μg/ml) in 400 μl of MEM supplemented with 2% FBS, MEM non-essential amino acids, 2 nM Lglutamine, 100 Units/ml penicilin, 0.1 mg/ml streptomycin and 12.5 Units/ml Nystatin (Biological Industries, Israel). In cases where the PRNT applied for sera evaluation, 3fold serially dilutions (ranging from 1:50 to 1:12,150) were used. 400 μl containing 300 PFU/ml of SARS-CoV-2 virus (GISAID accession EPI_ISL_406862) were then added to the mAb solution supplemented with 0.25% guinea pig complement sera (Sigma, Israel) and the mixture incubated at 37°C, 5% CO 2 for 1 h. 

J o u r n a l P r e -p r o o f

All animal experiments involving SARS-CoV-2 were conducted in a BSL3 facility.

Infection experiments were carried out using SARS-CoV-2 BavPat1/2020 strain (EVAg Ref-SKU: 026V-03883). SARS-CoV-2 virus diluted in PBS supplemented with 2% FBS (Biological Industries, Israel) was used to infect animals by intranasal instillation of anesthetized mice. For mAbs protection evaluation, mice were treated intraperitoneally by single administration of 1 ml volume, containing 0.1 and 0.01 mg Ab/mouse (equivalent of 5, and 0.5 mg/kg body weight, respectively) of the antibody 2 days following infection with 300 PFU SARS-CoV-2. Control groups were administered with PBS. Body weight was monitored daily throughout the follow-up period post infection.

Mice were evaluated once a day for clinical signs of disease and dehydration. Euthanasia was applied when the animals exhibited irreversible disease symptoms (rigidity, lack of any visible reaction to contact). Statistical analysis was performed to survival results using two-tailed log-rank Mantel-Cox test.

All Biolayer Interferometry assays were analyzed using the Octet Data analysis software (ForteBio, Version 8.1) and visualized using GraphPad Prism 5.

ELISA results were analyzed using Excel. Mean and SEM were calculated where appropriate, using Excel, and are presented in the relevant figures.

All the following statistical analyses were conducted using GraphPad Prism 5. For In vitro neutralization experiments, mean and SEM were calculated for each concentration, curves were fitted using nonlinear regression and IC 50 values were extrapolated from the resulting curves. Results are presented in the relevant figures, in the results section and in Table S1 . Area under curve (AUC) was calculated for epitope binning curves and used to create the heat map presented in Figure 2 . Two-tailed log-rank Mantel-Cox test was used 

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2 and are differentially expressed in lung and kidney epithelial and endothelial cells. bioRxiv

The Sialoside-Binding Pocket of SARS-CoV-2 Spike Glycoprotein Structurally Resembles MERS-CoV

Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now

A human synthetic combinatorial library of arrayable single-chain antibodies based on shuffling in vivo formed CDRs into general framework regions

Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Development of a tissue-culture-based enzyme-immunoassay method for the quantitation of anti-vaccinia-neutralizing antibodies in human sera

The coding capacity of SARS-CoV-2

Human coronavirus: host-pathogen interaction

Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity

SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors. bioRxiv

Safety and pharmacokinetics of the Fcmodified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

Clinical Characteristics of Coronavirus Disease 2019 in China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Human coronavirus HKU1 spike protein uses O-Acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme

ACE2 mouse models: a toolbox for cardiovascular and pulmonary research

Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

A biolayer interferometry-based assay for rapid and highly sensitive detection of biowarfare agents

Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions

Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Structural insights into neonatal Fc receptor-based recycling mechanism

Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays

A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease

Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease

Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors

C-type Lectin CD209L/L-SIGN and CD209/DC-SIGN: Cell Adhesion Molecules Turned to Pathogen Recognition Receptors

Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody

Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry

Cell entry mechanism of SARS-CoV-2

The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN. bioRxiv

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Structural basis for human coronavirus attachment to sialic acid receptors

Bitter-sweet symphony: glycan-lectin interactions in virus biology

Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Site-specific glycan analysis of the SARS-CoV-2 spike

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

IgBLAST: an immunoglobulin variable domain sequence analysis tool

K18-hACE2 mice develop respiratory disease resembling severe COVID-19

Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

Structural basis of a shared antibody response to SARS-CoV-2

Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein